See more : Wynn Macau, Limited (1128.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Infinity Pharmaceuticals, Inc. (INFI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Infinity Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- A-Sonic Aerospace Limited (ASNCF) Income Statement Analysis – Financial Results
- NaviFUS Corp. (6872.TWO) Income Statement Analysis – Financial Results
- Shop Apotheke Europe N.V. (SAE.DE) Income Statement Analysis – Financial Results
- UCB SA (UCBJY) Income Statement Analysis – Financial Results
- Joy Spreader Group Inc. (6988.HK) Income Statement Analysis – Financial Results
Infinity Pharmaceuticals, Inc. (INFI)
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59M | 1.86M | 1.72M | 3.05M | 22.15M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 34.84M | 51.56M | 49.83M | 41.32M | 41.13M | 36.26M | 13.08M | 6.20M | 3.10M | 400.00K | 0.00 |
| Cost of Revenue | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.11M | 29.44M | 31.67M | 35.49M | 24.86M | 9.90M | 7.87M | 2.80M | 1.30M | 200.00K | 0.00 |
| Gross Profit | 1.03M | 738.00K | 682.00K | -4.26M | 22.08M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 9.73M | 22.12M | 18.16M | 5.83M | 16.28M | 26.37M | 5.20M | 3.40M | 1.80M | 200.00K | 0.00 |
| Gross Profit Ratio | 39.72% | 39.72% | 39.67% | -139.69% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 27.93% | 42.91% | 36.44% | 14.10% | 39.57% | 72.71% | 39.78% | 54.84% | 58.06% | 50.00% | 0.00% |
| Research & Development | 32.41M | 31.65M | 26.76M | 27.12M | 19.76M | 20.83M | 119.61M | 199.11M | 143.63M | 99.76M | 118.60M | 108.58M | 99.23M | 77.86M | 47.47M | 33.79M | 35.79M | 3.92M | 4.30M | 2.55M | 6.22M | 12.98M | 8.93M | 3.54M | 5.10M | 4.10M | 2.60M | 600.00K |
| General & Administrative | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 0.00 | 21.07M | 19.46M | 16.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00M | 2.50M | 1.60M | 600.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 22.72M | 21.07M | 19.46M | 16.84M | 14.03M | 9.46M | 15.07M | 14.10M | 13.96M | 12.27M | 11.02M | 8.41M | 4.44M | 5.00M | 2.50M | 1.60M | 600.00K |
| Other Expenses | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | -6.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 45.82M | 39.18M | 41.41M | 34.01M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 24.72M | 19.41M | 17.03M | 70.21M | 30.92M | 30.55M | 8.65M | 10.00M | 6.70M | 4.20M | 1.20M |
| Cost & Expenses | 47.44M | 46.94M | 40.22M | 48.71M | 34.08M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 49.83M | 48.85M | 48.70M | 105.69M | 55.78M | 40.45M | 16.52M | 12.80M | 8.00M | 4.40M | 1.20M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 339.00K | 0.00 | 559.00K | 326.75K | 463.01K | 2.04M | 3.34M | 6.58M | 2.46M | 2.02M | 1.42M | 1.80M | 2.18M | 3.53M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 180.00K | 180.00K | 2.45M | 2.56M | 93.00K | 1.01M | 1.23M | 1.37M | 9.65M | 0.00 | 1.91M | 1.84M | 1.91M | 1.30M | 21.37K | 188.04K | 1.51M | 4.81K | 6.14K | 40.75K | 144.47K | 279.58K | 1.53M | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 458.00K | 480.00K | 483.00K | 219.00K | 191.00K | 1.72M | 3.42M | 2.29M | 1.77M | 1.82M | 1.64M | 2.10M | 2.18M | 2.15M | 1.97M | 2.81M | 3.69M | 6.23M | 6.71M | 5.29M | 57.04M | 12.60M | 13.20M | 671.71K | 600.00K | 200.00K | 0.00 | 0.00 |
| EBITDA | -44.84M | -44.60M | -38.01M | -45.66M | -11.74M | -43.33M | -30.89M | -127.11M | -7.58M | -125.85M | -52.81M | -36.10M | -48.97B | -47.77B | 24.45M | -20.48M | -26.76B | -16.04B | 9.60M | 8.24M | -64.38B | -14.65B | 17.89M | -2.64M | -5.40M | -4.60M | -4.00M | -1.20M |
| EBITDA Ratio | -1,729.43% | -2,400.59% | -2,211.40% | -1,497.67% | -53.00% | -722.12% | -764.34% | -116.54% | -4.60% | 0.00% | -205.82% | -38.91% | -66.98% | -63.66% | 29.30% | -83.48% | -116.38% | -9.51% | 18.62% | 16.54% | 106.23% | -4.95% | 49.32% | -20.20% | -87.10% | -148.39% | -1,000.00% | 0.00% |
| Operating Income | -44.84M | -45.08M | -38.50M | -45.66M | -11.93M | -36.45M | -30.89M | -127.11M | -7.92M | -127.68M | -52.81M | -38.53M | -48.97M | -47.77M | 19.14M | -23.29M | -26.76M | -16.04M | 2.72M | -748.49K | -64.38M | -14.65M | -4.18M | -3.45M | -6.60M | -4.80M | -4.00M | -1.20M |
| Operating Income Ratio | -1,729.43% | -2,426.43% | -2,239.50% | -1,497.67% | -53.87% | -607.42% | -164.99% | -116.54% | -4.80% | 0.00% | -112.09% | -41.53% | -68.65% | -96.44% | 22.94% | -94.92% | -144.70% | -46.03% | 5.27% | -1.50% | -155.83% | -35.61% | -11.53% | -26.36% | -106.45% | -154.84% | -1,000.00% | 0.00% |
| Total Other Income/Expenses | 475.00K | -179.00K | -2.00M | -1.45M | 676.00K | -6.11M | 790.00K | -933.00K | -9.31M | 896.00K | -1.16M | -1.51M | -713.27K | 14.94M | 4.52M | 6.39M | -598.01K | 2.33M | 1.24M | -1.82M | -51.23M | 3.50B | -8.87M | -133.92K | 300.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -44.37M | -45.26M | -40.49M | -47.11M | -11.25M | -42.55M | -30.10M | -128.04M | -17.23M | -126.78M | -53.96M | -40.04M | -49.68M | -32.83M | 23.65M | -16.90M | -27.36M | -13.71M | 3.96M | -2.57M | -115.61M | -14.66M | -13.05M | -3.58M | -6.30M | -4.80M | -4.00M | -1.20M |
| Income Before Tax Ratio | -1,711.11% | -2,436.06% | -2,355.56% | -1,545.13% | -50.81% | -709.17% | -160.77% | -117.40% | -10.44% | 0.00% | -114.54% | -43.16% | -69.65% | -66.28% | 28.35% | -68.87% | -147.94% | -39.35% | 7.68% | -5.16% | -279.82% | -35.64% | -35.98% | -27.39% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| Income Tax Expense | -1.11M | 180.00K | 2.45M | -54.00K | 769.00K | -720.00K | -2.19M | 335.00K | 183.00K | 0.00 | 1.91M | 326.75K | -700.32K | -329.57K | 21.37K | 0.00 | 1.09M | 13.24K | 55.58K | 65.59K | -2.27M | -3.50M | 7.51M | -76.72K | 600.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -43.26M | -45.44M | -42.94M | -47.06M | -11.25M | -41.83M | -30.10M | -128.38M | -17.42M | -126.78M | -53.96M | -40.04M | -48.98M | -32.51M | 23.65M | -16.90M | -28.45M | -14.16M | 3.90M | 1.06M | -62.11M | -11.15M | -11.70M | -3.37M | -6.30M | -4.80M | -4.00M | -1.20M |
| Net Income Ratio | -1,668.18% | -2,445.75% | -2,497.79% | -1,543.36% | -50.81% | -697.17% | -160.77% | -117.70% | -10.56% | 0.00% | -114.54% | -43.16% | -68.67% | -65.62% | 28.35% | -68.87% | -153.82% | -40.66% | 7.57% | 2.13% | -150.34% | -27.10% | -32.25% | -25.78% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| EPS | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.17 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| EPS Diluted | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.14 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| Weighted Avg Shares Out | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.24M | 19.51M | 7.46M | 2.14M | 1.82M | 1.29M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
| Weighted Avg Shares Out (Dil) | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.77M | 19.51M | 7.46M | 2.14M | 6.54M | 6.08M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc....
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company's special meeting on July 23, 2023. MEI issued the following...
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company's special meeting on July...
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing...
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. MEI issued the...
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced further design features of its Phase 2 MARIO-8 study in SCCHN. The adaptive design of the MARIO-8...
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. The Company noted...
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals announced today that ISS has recommended that Infinity stockholders vote for the merger with MEI Pharma, Inc.
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that MEI Pharma shareholders vote “FOR” the Company's pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”)...
Source: https://incomestatements.info
Category: Stock Reports